NMN injections deliver nicotinamide mononucleotide directly into the body instead of relying on absorption through the digestive system. That sounds appealing, but the research is still surprisingly thin.

So far, one small human study found that intravenous NMN increased blood NAD+ after a 300 mg dose and caused no major short-term safety issues during the observation period (1). That is interesting, but it is nowhere near enough evidence to say NMN injections slow aging or work better than oral NMN.

Key Takeaways:

• NMN is a precursor the body can use to make NAD+.

• Human research on NMN injections is extremely limited.

• A small study found that 300 mg of IV NMN increased blood NAD+ and appeared well tolerated over several hours (1).

• Oral NMN has a much larger human research base, and no strong clinical trial has shown injections provide better health outcomes.

What Are NMN Injections?

NMN, short for nicotinamide mononucleotide, is a naturally occurring molecule involved in the production of NAD+.

NAD+ plays a central role in cellular energy metabolism and several processes linked with cell repair and signaling.

NMN can be taken orally, but injectable forms bypass the digestive tract. Depending on the product and setting, injections may be given intravenously, intramuscularly, or under the skin.

There is an important distinction here.

NMN injections are not the same as NAD+ injections.

NMN is a precursor that the body converts into NAD+, while NAD+ injections deliver the finished coenzyme itself. Research on one should not automatically be used to support claims about the other.

What Does the Research Say About NMN Injections?

Human research is very limited. In one small study, researchers gave 300 mg of NMN intravenously to 10 healthy adults between the ages of 20 and 70 (1).

Blood NAD+ increased after the infusion. Researchers also reported a reduction in triglycerides during the testing period.

No significant changes were seen in blood pressure, heart rate, oxygen saturation, ECG measurements, or blood markers related to liver, kidney, pancreatic, and cardiac function during the short observation period (1).

That sounds promising, but the limitations matter.

The study:

• Included only 10 people

• Had no placebo group

• Examined a single IV dose

• Followed participants for only several hours

• Did not test longevity, cognition, exercise performance, or long-term health outcomes

A 2026 review of NAD+ therapies highlighted just how small this evidence base is. Among the available human literature, injectable NMN research remains limited to exploratory studies, while oral NMN has been tested in several randomized trials (2).

In other words, we know NMN can influence NAD-related markers. We do not yet know if injecting it leads to better health outcomes.

What Are NMN Injections Supposed to Do?

The main reason people use NMN is to support NAD+ production.

NAD+ helps cells convert nutrients into usable energy and supports enzymes involved in DNA repair, metabolic regulation, and cell signaling.

For that reason, NMN injections are sometimes promoted for:

• Healthy aging

• Energy

• Recovery

• Metabolic health

• Cellular function

There is a catch, though.

Increasing NAD+ does not prove that a treatment slows aging or improves longevity.

That distinction gets lost surprisingly easily.

Current research supports NMN's ability to influence NAD-related biomarkers. Clinical outcomes are much less consistent, and injectable NMN has barely been studied in comparison with oral NMN (2).

NMN Injections vs Oral NMN

The clearest difference is not just how they enter the body. It is how much research we have.

Oral NMN has been tested at doses ranging from a few hundred milligrams to 2,000 mg per day in human trials.

For example, one randomized study gave overweight or obese adults aged 45 and older 2,000 mg of NMN daily for 28 days. Blood NAD+ increased substantially during supplementation (3).

Another clinical trial tested 300, 600, and 900 mg of NMN daily for 60 days and reported increases in blood NAD+ across the treatment groups (4).

No strong head-to-head human trial has shown that NMN injections produce better health outcomes than oral NMN.

Bypassing digestion sounds more direct. More direct does not automatically mean more effective.

Are NMN Injections Safe?

The small IV NMN study reported no serious short-term adverse effects following the 300 mg infusion (1).

That is reassuring, but it cannot tell us much about:

• Regular injections

• Higher doses

• Long-term use

• Older adults with medical conditions

• Interactions with medications

Injectable products also carry practical risks that tablets do not, including infection, contamination, incorrect preparation, and injection-site complications.

This matters even more when products come from compounded or loosely regulated sources.

Anyone considering injectable NMN should discuss it with a qualified healthcare professional rather than treating it like a standard supplement.

NMN Injections vs NAD+ Injections

The names sound similar, but the molecules are different.

NMN sits earlier in the NAD+ pathway. Your body can convert NMN into NAD+.

NAD+ injections skip that precursor step and deliver NAD+ itself.

Neither route has a strong base of controlled human trials showing anti-aging benefits.

A recent review of intravenous NAD+ and NAD+ precursors found that injectable approaches remain poorly studied compared with oral precursors such as NMN and nicotinamide riboside (2).

Researchers also noted that no trials have properly compared clinical outcomes between these different routes and compounds.

That means claims that one method is clearly superior are getting ahead of the science.

Final Words

NMN injections are scientifically interesting, but there is still a large gap between what they may do biologically and what has been proven in people.

One small human study showed that IV NMN can raise blood NAD+ without obvious short-term safety problems. Beyond that, we still need larger controlled trials looking at repeat dosing, long-term safety, and meaningful health outcomes.

For now, oral NMN has the stronger human evidence base and is far easier to use.

At Omre, we take that more established route with our NMN + Resveratrol, which combines NMN with trans-resveratrol in a simple daily formula for people looking to support NAD+ production and healthy aging without injections.

FAQs

Do NMN injections increase NAD+?

A small human study found that a 300 mg intravenous NMN dose increased blood NAD+ levels (1). Larger studies are still needed.

Are NMN injections better than oral NMN?

There is no good human trial showing NMN injections provide better health outcomes than oral NMN. Oral NMN currently has far more clinical research behind it.

Are NMN injections safe?

One small study reported no major short-term safety issues after a single IV NMN infusion (1). Long-term safety and repeated dosing have not been well studied.

What is the difference between NMN and NAD+ injections?

NMN is a precursor the body can convert into NAD+. NAD+ injections deliver NAD+ itself. They are different compounds and should not be treated as interchangeable.

How much NMN is used in injections?

The best-known human IV NMN study used 300 mg. There is not enough research to establish a standard injectable NMN dose for general wellness or longevity.

References

1. Kimura et al. 2022, intravenous NMN study in healthy adults

2. Frontiers in Aging, 2026 review of intravenous NAD+ and NAD+ precursors

3. The Journal of Clinical Endocrinology & Metabolism, high-dose oral NMN trial

4. GeroScience, randomized NMN dose-response trial